Abstract
On behalf of CARI (Caring for Australasians with Renal Impairment; www.cari.org.au), the national kidney guidelines group of Australia-New Zealand, we would like to respond to the recent series of articles in CJASN on the role of industry in renal guideline development. CARI is funded through unrestricted educational grants from the pharmaceutical industry and the Australian government through a National Health and Medical Research Council Centre of Clinical Research Excellence grant. Unlike the Kidney Disease Outcomes Quality Initiative, individual guidelines are not funded; rather all funding provides core infrastructure to support all guideline activities. The annual budget of AU$300,000 has been adequate to fund development of two new major guidelines each year, update old guidelines (published for more than three years), and commence active guideline implementation projects. The evidence threshold we use for guideline statements is high. …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical Journal of the American Society of Nephrology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
